HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report issued on Tuesday, February 24th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.28) per share for the quarter, up from their prior forecast of ($0.29). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.79 EPS.

FULC has been the subject of several other reports. Royal Bank Of Canada upped their price target on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th. Cantor Fitzgerald boosted their price objective on shares of Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, January 22nd. Leerink Partners reaffirmed an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $23.00 price target (up from $16.00) on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $8.98 on Thursday. The company has a 50 day simple moving average of $10.73 and a 200 day simple moving average of $9.48. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $15.74. The firm has a market cap of $486.00 million, a PE ratio of -7.61 and a beta of 3.19.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31).

Insider Buying and Selling at Fulcrum Therapeutics

In related news, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the transaction, the insider owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Aberdeen Group plc increased its stake in shares of Fulcrum Therapeutics by 135.0% in the 3rd quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock valued at $1,269,000 after acquiring an additional 79,265 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Fulcrum Therapeutics by 63.5% in the second quarter. Acadian Asset Management LLC now owns 563,380 shares of the company’s stock worth $3,871,000 after purchasing an additional 218,819 shares during the period. Bailard Inc. bought a new stake in Fulcrum Therapeutics in the second quarter valued at $185,000. Campbell & CO Investment Adviser LLC bought a new stake in Fulcrum Therapeutics in the third quarter valued at $943,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Fulcrum Therapeutics by 57.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock valued at $2,357,000 after purchasing an additional 124,798 shares during the period. Institutional investors own 89.83% of the company’s stock.

Trending Headlines about Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: Phase 1b PIONEER (20 mg) data showed a large mean absolute HbF increase (from 7.1% to 19.3% at Week 12), improvements in hemolysis and hemoglobin, 7/12 patients reached ≥20% HbF, 58% had zero VOCs during treatment, and no treatment-related SAEs; company plans a potential registration‑enabling trial in H2 2026. Read More.
• Positive Sentiment: HC Wainwright initiated or reiterated bullish modeling with a Buy rating and $25 price target, projecting FY2030 EPS of $2.71 — a materially higher long‑term view than consensus and supportive for upside if clinical development progresses. Read More.
• Positive Sentiment: Stifel commented that the prior share move lower was “overdone,” signaling some sell‑side support for a rebound and reduced downside risk from the recent pullback. Read More.
• Neutral Sentiment: Q4 2025 results: Fulcrum reported (‑$0.31) EPS, in line with consensus; management held a conference call and reiterated development plans — meeting estimates removes an earnings disappointment but leaves focus squarely on clinical progress and the next trials. Read More.
• Neutral Sentiment: Earnings call transcript and investor Q&A are available for detail on runway, timing for a registration‑enabling study and safety/efficacy readouts — items investors will watch for upcoming catalysts. Read More.
• Negative Sentiment: Some headlines noted that the stock still tumbled at points despite the positive trial readout, indicating profit‑taking, short‑term volatility or skepticism about pathway/timing to approval and commercial potential. That volatility can pressure shares until a clear registrational plan and larger study data are available. Read More.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.